Theories of vaccination for Helicobacter pylori

  • W. F. Doe


Successful eradication of Helicobacter pylori infection leading to cure of peptic ulceration has led to intensive antimicrobical therapy involving combinations of antibiotics on a very large scale. However, the failures of chemotherapy due to compliance, cost, development of resistant organisms, the very high global prevalence of H. pylori infection, and its association with gastric malignancy provide a compelling case for considering other preventive strategies. Recent insights into the nature of antigen uptake by mucosal surfaces and recognition by T cells have suggested new strategies for antigen delivery by oral vaccines, for overcoming oral tolerance and for enhancing mucosal immune responses. The concept of developing an oral vaccine to prevent H. pylori infection in humans however, poses several questions. Why doesn’t the readily detected antibody response found in infected patients kill the organism? Why doesn’t previous infection protect against reinfection? Given the finding that H. pylori infection occurs in infancy or early childhood in developing countries, will immunization of already-infected populations provide any therapeutic benefit? Are there concerns about the ability of H. pylori vaccines to eliminate all the Helicobacter strains?


Pylorus Infection Mucosal Immune Response Oral Vaccine Oral Immunization Edible Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ogra PL, Karzon DT. Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine. J Immunol. 1969;102:1423–30.PubMedGoogle Scholar
  2. 2.
    Staats HF, Jackson RJ, Marinaro M, Takahashi I, Kiyono H, McGhee JR. Mucosal immunity to infection with implications for vaccine development. Curr Opin Immunol. 1994;6:572–83.PubMedCrossRefGoogle Scholar
  3. 3.
    Jaskiewicz K, Loow JA, Marks IN. Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori. Dig Dis Sci. 1993;38: 937–43.PubMedCrossRefGoogle Scholar
  4. 4.
    Blaser MJ. Hypothesis on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology. 1992;102:720–7.PubMedGoogle Scholar
  5. 5.
    Czinn SJ, Cai A, Nedrud JG. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine. 1993; 11:636–42.CrossRefGoogle Scholar
  6. 6.
    Radcliff FJ, Ramsay AJ, Lee A. Failure of immunisation against Helicobacter infection in IL-4 deficient mice: evidence for a TH2 immune response as the basis for protective immunity. Gastroenterology. 1995;939:A3754.Google Scholar
  7. 7.
    Lee CK, Weltzin R, Thomas WD Jr et al. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis. 1995;172:161–72.PubMedCrossRefGoogle Scholar
  8. 8.
    Goodwin S. Helicobacters shed new light on chaperonins. Lancet. 1995;346:653–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Dertzbaugh MT, Elson CO. Cholera toxin as a mucosal adjuvant. Topics Vaccine Adjuvant Res. 1991;11:119–31.Google Scholar
  10. 10.
    Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol Today. 1990; 11:89–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Mowat A McI, Donachie AM. ISCOMS — a novel strategy for mucosal immunization? Immunol Today. 1991;12:383–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Mowat A McI, Maloy KJ, Donachie AM. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology. 1993;80:527–34.PubMedGoogle Scholar
  13. 13.
    Pardoll DM, Beckerieg AM. Exposing the immunology of naked DNA vaccines. Immunology. 1995;3:165–9.Google Scholar
  14. 14.
    Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci. 1993;90:11478–82.PubMedCrossRefGoogle Scholar
  15. 15.
    Moffat AS. Exploring transgenic plants as a new vaccine source. Science. 1995;268:658–60.PubMedCrossRefGoogle Scholar
  16. 16.
    Haq TA, Mason HS, Clements JD, Amtzen CJ. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science. 1995;268:714–16.PubMedCrossRefGoogle Scholar
  17. 17.
    Leong KH, Ramsay AJ, Boyle DB, Ramshaw IA. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol. 1994;8125–30.Google Scholar
  18. 18.
    Thomas JE, Austin S, Dale A et al. Protection by human milk IgA against Helicobacter pylori infection in infancy. Lancet. 1993;342:121.PubMedCrossRefGoogle Scholar
  19. 19.
    Corthesy-Theulaz I, Porta N, Glauser M et al. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology. 1995; 109:115–21.PubMedCrossRefGoogle Scholar
  20. 20.
    Doidge C, Gust I, Lee A, Buck F, Hazell S, Manne U. Therapeutic immunisation against Helicobacter infection. Lancet. 1994;343:914–15.PubMedCrossRefGoogle Scholar
  21. 21.
    Cuenca R, Blanchard T, Lee C et al. Therapeutic immunization against Helicobacter mustelae infection in naturally infected ferrets. Gastroenterology. 1995;108:A78.Google Scholar

Copyright information

© Kluwer Academic Publishers and Axcan Pharma 1996

Authors and Affiliations

  • W. F. Doe

There are no affiliations available

Personalised recommendations